Hualing Pharmaceuticals (02552.HK) Achieves Profit for the First Time in the First Half of the Year, Overseas Expansion Speeds Up

According to the Wisdom Finance APP, on August 28, 2025, Hualing Pharmaceuticals (02552.HK) announced its unaudited interim results for the six months ended June 30, 2025. During the reporting period, sales of Huatangning reached 1.764 million boxes, a year-on-year increase of 108%, with a net sales of 2.174 billion yuan, a year-on-year increase of 112%. Since taking over the commercial operation of Huatangning in January 2025, the company has achieved significant growth with its own sales team, and with the continued expansion of medical insurance coverage, prescriptions in secondary and tertiary hospitals have significantly increased, and the overall commercialization effects have been significant.